Comparative analysis of RNA expression identifies effective targeted drug in myoepithelial carcinoma

Area of Science:

• Oncology
• Genomics
• Pediatric Cancer Research

Background:

• Myoepithelial carcinoma is an ultra-rare pediatric solid tumor lacking targeted treatment options.
• The clinical utility of tumor RNA sequencing (RNA-Seq) for identifying therapeutic targets in pediatric cancers remains underexplored.
• The Comparative Analysis of RNA Expression (CARE) framework was previously developed to integrate RNA-Seq data into clinical decision-making for difficult-to-treat pediatric cancers.

Purpose of the Study:

• To evaluate the effectiveness of the CARE framework in identifying actionable therapeutic targets for a pediatric patient with myoepithelial carcinoma.
• To demonstrate the clinical benefit of analyzing large-scale genomic datasets for rare pediatric cancers.
• To highlight the importance of data sharing in advancing precision oncology for rare diseases.

Main Methods:

• A 4-year-old male patient with metastatic myoepithelial carcinoma underwent standard-of-care tumor DNA profiling.
• Tumor RNA sequencing (RNA-Seq) was performed on a metastatic lung nodule.
• The patient's RNA-Seq profile was analyzed using the CARE framework, comparing it against over 11,000 public tumor profiles.
• Overexpression biomarkers were identified through comparative analysis.

Main Results:

• Standard DNA profiling did not identify any actionable mutations for targeted therapy.
• The CARE analysis successfully identified overexpression biomarkers.
• Based on CARE findings, a targeted treatment was nominated, resulting in a durable clinical response for the patient.
• The study demonstrated the feasibility of integrating comprehensive genomic analysis into the clinical management of rare pediatric tumors.

Conclusions:

• The CARE framework, utilizing tumor RNA sequencing and large-scale data comparison, is a valuable tool for identifying therapeutic targets in rare pediatric cancers.
• Concurrent analysis of large genomic datasets, coupled with data sharing, can lead to significant clinical benefits, especially for cancers with unknown drivers.
• This case underscores the potential of precision medicine approaches, even in the absence of traditional genetic biomarkers, for improving outcomes in ultra-rare pediatric malignancies.